1. Pink Sheet

BIO Stalwart Greenwood Announces Departure

 
• By Derrick Gingery

Long-time CEO of the Biotechnology Innovation Organization will remain until after the 2020 election and help with the leadership transition.

Medical engineering concept_227959225_1200.jpg
While at BIO, Jim Greenwood helped lead PDUFA negotiations and open the US market to biosimilars. • Source: Shutterstock

Jim Greenwood's upcoming departure as president and CEO of the Biotechnology Innovation Organization sets up a candidate search for the trade group's top job, a process it has not engaged in often, and may be among the reasons the transition to new leadership will take more than a year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

More from Pink Sheet

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

New EU Filings

 
• By Neena Brizmohun

Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.